The invention relates to the use of the monoclonal antibody NILO1 for the diagnosis, treatment and/or prevention of brain tumors and lesions. Particularly, the invention relates to methods for the diagnosis of brain tumors and brain lesions in which cells marked with said antibody, or with immunologically active fragments thereof, are detected. The invention also relates to the use of said monoclonal antibody, or immunologically active fragments thereof, as a medicament for the treatment and/or prevention of brain tumors and brain lesions. In a preferred embodiment of the invention, the monoclonal antibody NILO1, or its immunologically active fragments, are humanized.

Provided herein are methods of assessing or determining the presence or absence of particles, such as bead particles, present in a cell composition. Also provided are articles of manufacture and kits for use in the methods.

The invention relates to using serum exosomal proteins, α-synuclein and clusterin, as biomarkers in the prediction and identification of a subject having Parkinson's Disease, and provides methods for determining their levels. The biomarkers are also useful for monitoring, prevention and/or treatment of Parkinson's Disease and in differentiating Parkinson's disease from atypical parkinsonian syndromes including MSA.

Provided herein are methods of assessing or determining the presence or absence of particles, such as bead particles, present in a cell composition. Also provided are articles of manufacture and kits for use in the methods.

Disclosed are systems, methods, and computer software for determining a conformational change in a structure of a protein. One method includes delivering a magnetic nanoparticle-nanobody (MNP-NB) complex to a sample containing a protein, where the MNP-NB complex will bind to the protein in the sample. An external magnetic field is applied to the sample with a magnetic field generation system. Signals are detected from the MNP-NB complex that reflect a response to the external magnetic field and a conformational change in a structure of the protein in the sample is determined from the signals.

Disclosed probes comprise metal nanoparticle cores associated with magnetic particles that allow probes associated with targets to be concentrated by an applied magnetic field to increase detection sensitivity and provide sufficient spacing between concentrated probes to avoid signal quenching. The probe may comprise at least one recognition receptor, and may further comprise at least one reporter molecule, such as a fluorescent tag, a Raman reporter, or combinations thereof. Concentrating probe-target composites substantially enhances a sensing signal, such as from 5 to 10 times, compared to detection without concentrating the probes. The method may be used to detect, for example, interleukins at concentrations at least as low as 25 pg/ml in sputum or blood from a subject for early and precise profiling of viral infections, such as SARS-CoV-2 infections.

The present disclosure relates to an extracellular vesicle purification material and purification method. The purification method adopts metal oxide microspheres or magnetic beads that can reversibly bind to phosphatidylserine to purify extracellular vesicles, and the purification material comprises nano zirconium dioxide microspheres, nano titanium dioxide microspheres or nano aluminum oxide microspheres, nano zirconium dioxide magnetic microspheres, nano titanium dioxide magnetic microspheres or nano aluminum oxide magnetic microspheres, and porous zirconium dioxide nano microspheres, porous titanium dioxide nano microspheres or porous aluminum oxide nano microspheres. The purification method of the present disclosure can quickly purify multiple samples: serum/plasma, urine and cell culture supernatant, has a moderate flux so as to retain extracellular vesicles to the greatest extent, and can obtain high-purity extracellular vesicles, without chelating agents and other reagents that may affect subsequent experiments, via elution.

The disclosure provides methods and kits for preparing a protein analyte for characterization. The method comprises pretreating a protein analyte in the presence of a magnetic bead in a changing magnetic field; and enzymatically digesting the protein analyte with an endopeptidase enzyme to provide a plurality of peptides for analysis by, for example, LC-MS/MS. The process can be performed in a single tube without the need for desalting or buffer exchange, in less than 2 hours.

Disclosed herein are monodisperse superparamagnetic beads, having a core-shell structure, and a method for preparing the beads.

The invention relates to isolating a selected population of exosomes with high specificity, thereby allowing accurate determination of exosomal protein content which is useful in the prediction and identification of a subject having Parkinson's Disease and in differentiating Parkinson's disease from atypical parkinsonian syndromes including MSA.